Latest news with #SudarshanPharmaIndustriesLimited
India.com
4 days ago
- Business
- India.com
Stock market news: Shares of this pharma company in focus after this status update from Ministry of Commerce and Industry
Stock market- File image- For Representational purpose Stock market news: Sudarshan Pharma Industries Limited (SPIL), an Indian pharmaceutical company, focuses on the manufacture, sourcing, and distribution of chemicals and pharmaceutical products. In a significant development, the company announced on Wednesday that it has been granted a certificate of recognition as a One Star Export House by the Directorate General of Foreign Trade under the Department of Commerce, Ministry of Commerce and Industry, Government of India. This recognition, which is valid for five years from May 8, 2023, to March 31, 2028, is expected to bring the small-cap stock in the specialty chemical sector into the spotlight. As of 12:16 IST on Thursday, June 6, the stock was trading at its 3% lower circuit limit at ₹30.38 per share, with a market capitalization of ₹731.12 crore. Furthermore, the company has announced that its Extraordinary General Meeting (EGM) will take place on Thursday, June 12, 2025. The remote e-voting period will begin on Monday, June 9, 2025, at 9:00 a.m. and end on Wednesday, June 11, 2025, at 5:00 p.m. The remote e-voting module will be disabled by NSDL after this period. Members whose names appear in the Register of Members or as Beneficial Owners on the record date (cut-off date), which is Thursday, June 5, 2025, may cast their votes electronically. Voting rights will be proportionate to each shareholder's share in the paid-up equity capital of the company as of the cut-off date, Thursday, June 5, 2025, as stated by Sudarshan Pharma in a stock exchange filing. For the bulk drug industry, the central government has allocated ₹100 billion. Of this amount, ₹30 billion will be used to promote the development of three bulk drug parks over the next five years, while ₹69.4 billion will support a production-linked incentive scheme designed to enhance the domestic production of critical key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs) over the next eight years. Since most of the 53 essential APIs and intermediates identified in this scheme are necessary for producing crucial medications and India is heavily reliant on imports from China, Sudarshan Pharma is establishing a manufacturing facility to produce some of these critical APIs that are currently imported from China.
Mint
04-05-2025
- Business
- Mint
325% rally in five years! Multibagger pharma stock in focus; here's why
Multibagger stock: Pharma company Sudarshan Pharma Industries share price will remain in focus in Monday's trading session after the company reported its half yearly and FY25 financial & operational performance on Friday. The multibagger pharma stock was down 1.99 per cent to close at ₹ 26.66 apiece on May 2. Sudarshan Pharma Industries shares have given mutlibagger returns to its investors by soaring over 325 per cent in five years. In the second half of FY25 (H2FY25), Sudarshan Pharma Industries Limited (SPIL) reported a 19% rise in net sales to ₹ 277 crore and a 43% increase in net profit to ₹ 7 crore compared to H2FY24. For the full fiscal year FY25, net sales rose by 9% to ₹ 505 crore, while net profit surged by 45% to ₹ 16 crore year-on-year. The company, currently valued at ₹ 642 crore in market capitalization, has achieved a strong compound annual profit growth of 37% over the past five years. SPIL is actively working to boost its exports and increase domestic sales of its manufactured medicines, the pharma company said in its investor's presentation. Additionally, it aims to improve profit margins from reselling Active Pharmaceutical Ingredients (API) in India. This strategic focus contributed to a significant rise in EBITDA margin in H2FY25, which in turn drove strong growth in Profit After Tax during the same period. India's pharmaceutical industry was valued at approximately $42 billion in 2021 and is projected to rise to around $50 billion by 2024. Forecasts suggest it could reach nearly $66 billion by 2025 and potentially expand to between $120 billion and $130 billion by 2030. India fulfills 40% of the United States' generic drug requirements and supplies 25% of the medicines used in the United Kingdom. Globally, India contributes 20% of total medicine production by volume and meets about 60% of the world's vaccine demand, solidifying its position as the leading supplier of generic drugs. Founded in 2008, Sudarshan Pharma is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products. The Company specializes in host of products from rock chemicals intermediates and API to finish formulations and fully integrated pharmaceutical and chemicals. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions. First Published: 4 May 2025, 01:51 PM IST
